Translational advances in pleural malignancies

Respirology

Volumn 16, Issue 1, 2011, Pages 53-63

  Stathopoulos, Georgios T ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

Adenocarcinoma; Diphosphonate; Inflammation; Malignant pleural effusion; Mesothelioma

Indexed keywords

BELINOSTAT; BETA INTERFERON; BIOLOGICAL MARKER; BORTEZOMIB; CISPLATIN; DOCETAXEL; DOXORUBICIN; ENTINOSTAT; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; FOLIC ACID ANTAGONIST; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 2; MESOTHELIN; MONOCLONAL ANTIBODY; PACLITAXEL; PANOBINOSTAT; PEMETREXED; PICIBANIL; RANPIRNASE; VALPROIC ACID; VORINOSTAT; ZOLEDRONIC ACID;

CANCER GROWTH; CLINICAL TRIAL; DRUG EFFECT; GENE CONTROL; GENE EXPRESSION; GENE THERAPY; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; PLEURA DISEASE; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PLEURA METASTASIS; PLEURA TUMOR; PLEURODESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; FOLIC ACID ANTAGONISTS; GPI-LINKED PROTEINS; HISTONE DEACETYLASE INHIBITORS; HUMANS; MESOTHELIOMA; MICE; PLEURAL EFFUSION; PLEURAL NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; TRANSLATIONAL RESEARCH; TUMOR MARKERS, BIOLOGICAL;

EID: 79952267121     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2010.01890.x     Document Type: Review

References (130)

1. Robinson BW, Lake RA. Advances in malignant mesothelioma. N. Engl. J. Med. 2005; 353: 1591-603.
2. Scherpereel A, Astoul P, Baas P et al. Guidelines of the ERS/ ESTS for management of malignant pleural mesothelioma. Eur. Respir. J. 2010; 35: 479-95.
3. Lee YCG, Light RW. Management of malignant pleural effusions. Respirology 2004; 9: 148-56. (Pubitemid 38937386)
4. Antony VB, Loddenkemper R, Astoul P et al. Management of malignant pleural effusions. Am. J. Respir. Crit. Care Med. 2000; 162: 1987-2001.
5. Francart J, Vaes E, Henrard S et al. A prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: a combined analysis of 10 EORTC trials. Eur. J. Cancer 2009; 45: 2304-11.
6. Bielsa S, Salud A, Martínez M et al. Prognostic significance of pleural fluid data in patients with malignant effusion. Eur. J. Intern. Med. 2008; 19: 334-9.
7. Grigoriu B, Scherpereel A. Screening for malignant mesothelioma - looking for the holy grail. Am. J. Respir. Crit. Care Med. 2009; 179: 851.
8. Porcel JM, Alemán C, Bielsa S et al. A decision tree for differentiating tuberculous from malignant pleural effusions. Respir. Med. 2008; 102: 1159-64.
9. Nagrath S, Sequist LV, Maheswaran S. Isolation of rare circulating tumor cells in cancer patients by microchip technology. Nature 2007; 450: 1235-9.
10. Rahman NM, Davies HE, Salzberg M et al. Use of lipoteichoic acid-T for pleurodesis in malignant pleural effusion: a phase I toxicity and dose-escalation study. Lancet Oncol. 2008; 9: 946-52.
11. Burgers JA, Kunst PW, Koolen MG et al. Pleural drainage and pleurodesis: implementation of guidelines in four hospitals. Eur. Respir. J. 2008; 32: 1321-7.
12. Lee YC, Wilkosz S. Malignant pleural effusions: fixing the leaky faucet. Am. J. Respir. Crit. Care Med. 2008; 178: 3-5.
13. Postmus PE, Brambilla E, Chansky K et al. International Association for the Study of Lung Cancer International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J. Thorac. Oncol. 2007; 2: 686-93.
14. Fennell DA, Gaudino G, O'Byrne KJ et al. Advances in the systemic therapy of malignant pleural mesothelioma. Nat. Clin. Pract. Oncol. 2008; 5: 136-47.
15. Jemal A, Siegel R, Xu J et al. Cancer Statistics, 2010. CA Cancer J. Clin. 2010; 60: 27-300.
16. Altekruse SF, Kosary CL, Krapcho M et al. (eds). SEER Cancer Statistics Review, 1975-2007. National Cancer Institute, Bethesda, MD, 2010. [Accessed 15 November 2010.] Available from URL: http://seer.cancer.gov/csr/1975-2007/, based on November 2009 SEER data submission, posted to the SEER website.
17. Stathopoulos GT, Hegmans JP, Lee YCG. Translational research in pleural diseases. In: Bouros D (ed.) Pleural Disease, 2nd edn. Informa Healthcare, New York, 2009; 182-97.
18. Stathopoulos GT, Lee YC. Experimental models: pleural diseases other than mesothelioma. In: Light RW, Lee YC (eds) Textbook of Pleural Diseases, 2nd edn. Hodder-Arnold, London, 2008; 169-86.
19. Stathopoulos GT, Kalomenidis I. Animal models of malignant pleural effusion. Curr. Opin. Pulm. Med. 2009; 15: 343-52.
20. Robinson BW, Creaney J, Lake R et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003; 362: 1612-16. (Pubitemid 37443528)
21. Pass HI, Lott D, Lonardo F et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N. Engl. J. Med. 2005; 353: 1564-73.
22. Park EK, Sandrini A, Yates DH et al. Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study. Am. J. Respir. Crit. Care Med. 2008; 178: 832-7.
23. Grigoriu BD, Scherpereel A, Devos P et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin. Cancer Res. 2007; 13: 2928-35.
24. Moschos C, Porfiridis I, Psallidas I et al. Osteopontin is up-regulated in malignant and inflammatory pleural effusions. Respirology 2009; 14: 716-22.
25. Davies HE, Sadler RS, Bielsa S et al. Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions. Am. J. Respir. Crit. Care Med. 2009; 180: 437-44.
26. Wheatley-Price P, Yang B, Patsios D et al. Soluble mesothelin-related peptide and osteopontin as markers of response in malignant mesothelioma. J. Clin. Oncol. 2010; 28: 3316-22.
27. Hassan R, Bullock S, Premkumar A et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin. Cancer Res. 2007; 13: 5144-9.
28. Raiko I, Sander I, Weber DG et al. Development of an enzyme-linked immunosorbent assay for the detection of human calretinin in plasma and serum of mesothelioma patients. BMC Cancer 2010; 10: 242.
29. Shigematsu Y, Hanagiri T, Kuroda K et al. Malignant mesothelioma- associated antigens recognized by tumor-infiltrating B cells and the clinical significance of the antibody titers. Cancer Sci. 2009; 100: 1326-34.
30. Saliba AE, Saias L, Psychari E et al. Microfluidic sorting and multimodal typing of cancer cells in self-assembled magnetic arrays. Proc. Natl. Acad. Sci. USA 2010; 107: 14524-9.
31. Bidlingmaier S, He J, Wang Y et al. Identification of MCAM/ CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma. Cancer Res. 2009; 69: 1570-77.
32. Liang QL, Shi HZ, Qin XJ et al. Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis. Thorax 2008; 63: 35-41.
33. Bielsa S, Esquerda A, Salud A et al. High levels of tumor markers in pleural fluid correlate with poor survival in patients with adenocarcinomatous or squamous malignant effusions. Eur. J. Intern. Med. 2009; 20: 383-6.
34. Daniil ZD, Zintzaras E, Kiropoulos T et al. Discrimination of exudative pleural effusions based on multiple biological parameters. Eur. Respir. J. 2007; 30: 957-64.
35. Tsuji S, Tsuura Y, Morohoshi T et al. Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion. Br. J. Cancer 2010; 103: 517-23.
36. Savic S, Franco N, Grilli B et al. Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology. Chest 2010; 138: 137-44.
37. Roncella S, Ferro P, Franceschini MC et al. Diagnosis and origin determination of malignant pleural effusions through the use of the breast cancer marker human mammaglobin. Diagn. Mol. Pathol. 2010; 19: 92-8.
38. Yuan Y, Nymoen DA, Dong HP et al. Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma frombreast carcinoma and malignant mesothelioma in serous effusions. Hum. Pathol. 2009; 40: 1453-60.
39. Amatya VJ, Takeshima Y, Kohno H et al. Caveolin-1 is a novel immunohistochemical marker to differentiate epithelioid mesothelioma from lung adenocarcinoma. Histopathology 2009; 55: 10-19.
40. Bueno R, De Rienzo A, Dong L et al. Second generation sequencing of the mesothelioma tumor genome. PLoS ONE 2010; 5: e10612.
41. Sugarbaker DJ, Richards WG, Gordon GJ et al. Transcriptome sequencing of malignant pleural mesothelioma tumors. Proc. Natl. Acad. Sci. USA 2008; 105: 3521-6.
42. Crispi S, Calogero RA, Santini M et al. Global gene expression profiling of human pleural mesotheliomas: identification of matrix metalloproteinase 14 (MMP-14) as potential tumour target. PLoS ONE 2009; 4: e7016.
43. Røe OD, Anderssen E, Helge E et al. Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype. PLoS ONE 2009; 4: e6554.
44. Christensen BC, Marsit CJ, Houseman EA et al. Differentiation of lung adenocarcinoma, pleural mesothelioma, and nonmalignant pulmonary tissues using DNA methylation profiles. Cancer Res. 2009; 69: 6315-21.
45. Christensen BC, Houseman EA, Godleski JJ et al. Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome. Cancer Res. 2009; 69: 227-34.
46. Goto Y, Shinjo K, Kondo Y et al. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. Cancer Res. 2009; 69: 9073-82.
47. Pass HI, Goparaju C, Ivanov S et al. hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma. Cancer Res. 2010; 70: 1916-24.
48. Ivanov SV, Goparaju CM, Lopez P et al. Pro-tumorigenic effects of miR-31 loss in mesothelioma. J. Biol. Chem. 2010; 285: 22809-17.
49. Kuramitsu Y, Miyamoto H, Tanaka T et al. Proteomic differential display analysis identified upregulated astrocytic phosphoprotein PEA-15 in human malignant pleural mesothelioma cell lines. Proteomics 2009; 9: 5078-89.
50. Fasola G, Belvedere O, AitaMet al. Low-dose computed tomography screening for lung cancer and pleural mesothelioma in an asbestos-exposed population: baseline results of a prospective, nonrandomized feasibility trial-an Alpe - adria Thoracic Oncology Multidisciplinary Group Study (ATOM 002). Oncologist 2007; 12: 1215-24.
51. Kim KW, Choi HJ, Kang S et al. The utility of multi-detector computed tomography in the diagnosis of malignant pleural effusion in the patients with ovarian cancer. Eur. J. Radiol. 2010; 75: 230-5.
52. Metintas M, Ak G, Dundar E et al. Medical thoracoscopy vs CT scan-guided Abrams pleural needle biopsy for diagnosis of patients with pleural effusions: a randomized, controlled trial. Chest 2010; 137: 1362-8.
53. Qureshi NR, Rahman NM, Gleeson FV. Thoracic ultrasound in the diagnosis of malignant pleural effusion. Thorax 2009; 64: 139-43.
54. Wrightson JM, Fysh E, Maskell NA et al. Risk reduction in pleural procedures: sonography, simulation and supervision. Curr. Opin. Pulm. Med. 2010; 16: 340-50.
55. Mavi A, Basu S, Cermik TF et al. Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease. Mol. Imaging Biol. 2009; 11: 369-78.
56. Sørensen JB, Ravn J, Loft A et al. Nordic Mesothelioma Group. Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy- D-glucose positron emission tomography/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy. Eur. J. Cardiothorac. Surg. 2008; 34: 1090-96.
57. Tan C, Barrington S, Rankin S et al. Role of integrated 18-fluorodeoxyglucose position emission tomography-computed tomography in patients surveillance after multimodality therapy of malignant pleural mesothelioma. J. Thorac. Oncol. 2010; 5: 385-8.
58. Francis RJ, Byrne MJ, van der Schaaf AA et al. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J. Nucl. Med. 2007; 48: 1449-58.
59. Lee ST, Ghanem M, Herbertson RA et al. Prognostic value of 18F-FDG PET/CT in patients with malignant pleural mesothelioma. Mol. Imaging Biol. 2009; 11: 473-9.
60. Ceresoli GL, Chiti A, Santoro A. 11C-labeled methionine and evaluation of malignant pleural mesothelioma. N. Engl. J. Med. 2007; 357: 1982-4.
61. Tsuji AB, Sogawa C, Sugyo A et al. Comparison of conventional and novel PET tracers for imaging mesothelioma in nude mice with subcutaneous and intrapleural xenografts. Nucl. Med. Biol. 2009; 36: 379-88.
62. Stathopoulos GT, Zhu Z, Everhart MB et al. Nuclear Factor-kB activation affects tumor progression in a mouse model of malignant pleural effusion. Am. J. Respir. Cell. Mol. Biol. 2006; 34: 142-50.
63. Duysinx B, Corhay JL, Larock MP et al. Prognostic value of metabolic imaging in non-small cell lung cancers with neoplasic pleural effusion. Nucl. Med. Commun. 2008; 29: 982-6.
64. Hasegawa S, Koshikawa-Yano M, Saito S et al. Molecular imaging of mesothelioma by detection of manganesesuperoxide dismutase activity using manganese-enhanced magnetic resonance imaging. Int. J. Cancer 2010, July 8. [Epub ahead of print].
65. Plathow C, Klopp M, Thieke C et al. Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT. Eur. Radiol. 2008; 18: 1635-43.
66. Janssen JP, Collier G, Astoul P et al. Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study. Lancet 2007; 369: 1535-9.
67. Marchi E, Vargas FS, Acencio MM et al. Pleurodesis: a novel experimental model. Respirology 2007; 12: 500-4. (Pubitemid 46961827)
68. Paschoalini Mda S, Vargas FS, Marchi E et al. Prospective randomized trial of silver nitrate vs talc slurry in pleurodesis for symptomatic malignant pleural effusions. Chest 2005; 128: 684-9. (Pubitemid 41140496)
69. Guo Y, Tang K, Bilaceroglu S et al. Iodopovidone is as effective as doxycycline in producing pleurodesis in rabbits. Respirology 2010; 15: 119-25.
70. Neto JD, de Oliveira SF, Vianna SP et al. Efficacy and safety of iodopovidone pleurodesis in malignant pleural effusions. Respirology 2010; 15: 115-18.
71. Light RW, Cheng DS, Lee YC et al. A single intrapleural injection of transforming growth factor-beta(2) produces an excellent pleurodesis in rabbits. Am. J. Respir. Crit. Care Med. 2000; 162: 98-104.
72. Sterman DH, Treat J, Litzky LA et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patientswith localizedmalignancy: results of a phase I clinical trial in malignant mesothelioma. Hum. Gene Ther. 1998; 9: 1083-92.
73. Saloura V, Wang LC, Fridlender ZG et al. Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy. Hum. Gene Ther. 2010; 21: 51-64.
74. Fukazawa T, Matsuoka J, Naomoto Y et al. Malignant pleural mesothelioma-targeted CREBBP/EP300 inhibitory protein 1 promoter system for gene therapy and virotherapy. Cancer Res. 2008; 68: 7120-29.
75. Gauvrit A, Brandler S, Sapede-Peroz C et al. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. Cancer Res. 2008; 68: 4882-92.
76. Watanabe M, Boyer JL, Crystal RG. AAVrh.10-mediated genetic delivery of bevacizumab to the pleura to provide local anti- VEGF to suppress growth of metastatic lung tumors. Gene Ther. 2010; 17: 1042-51.
77. Sterman DH, Recio A, Haas AR et al. A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions. Mol. Ther. 2010; 18: 852-60.
78. Iankov ID, Msaouel P, Allen C et al. Demonstration of antitumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model. Breast Cancer Res. Treat. 2010; 122: 745-54.
79. Wang X, Zhou J, Wang Y et al. A phase I clinical and pharmacokinetic study of paclitaxel liposome infused in non-small cell lung cancer patients with malignant pleural effusions. Eur. J. Cancer 2010; 46: 1474-80.
80. Jones DR, Taylor MD, Petroni GR et al. Phase I trial of intrapleural docetaxel administered through an implantable catheter in subjects with a malignant pleural effusion. J. Thorac. Oncol. 2010; 5: 75-81.
81. Yoshida K, Sugiura T, Takifuji N et al. Randomized phase II trial of three intrapleural therapy regimens for the management of malignant pleural effusion in previously untreated non-small cell lung cancer: JCOG 9515. Lung Cancer 2007; 58: 362-8. (Pubitemid 350051515)
82. Suzuki M, Endo K, Satoh H et al. A novel concept of treatment of diffuse or multiple pleural tumors by boron neutron capture therapy (BNCT). Radiother. Oncol. 2008; 88: 192-5.
83. Lencioni R, Crocetti L, Cioni R et al. Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). Lancet Oncol. 2008; 9: 621-8.
84. van Meerbeeck JP, Gaafar R, Manegold C et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J. Clin. Oncol. 2005; 23: 6881-9.
85. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2003; 21: 2636-44.
86. Jassem J, Ramlau R, Santoro A et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J. Clin. Oncol. 2008; 26: 1698-704.
87. Dickgreber NJ, Sorensen JB, Paz-Ares LG et al. Pemetrexed safety and pharmacokinetics in patients with third-space fluid. Clin. Cancer Res. 2010; 16: 2872-80.
88. Racanelli AC, Rothbart SB, Heyer CL et al. Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. Cancer Res. 2009; 69: 5467-74.
89. Riganti C, Doublier S, Aldieri E et al. Asbestos induces doxorubicin resistance in MM98 mesothelioma cells via HIF-1alpha. Eur. Respir. J. 2008; 32: 443-51.
90. Kosuri KV, Wu X, Wang L et al. An epigenetic mechanism for capecitabine resistance in mesothelioma. Biochem. Biophys. Res. Commun. 2010; 391: 1465-70.
91. Vandermeers F, Hubert P, Delvenne P et al. Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Clin. Cancer Res. 2009; 15: 2818-28.
92. Scherpereel A, Berghmans T, Lafitte JJ et al. for the European Lung Cancer Working Party (ELCWP). Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study. Eur. Respir. J. 2010, July 7. [Epub ahead of print].
93. Porta C, Paglino C, Mutti L. Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma. Biologics 2008; 2: 601-9.
94. Mikulski SM, Costanzi JJ, Vogelzang NJ et al. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J. Clin. Oncol. 2002; 20: 274-81.
95. Turcotte RF, Lavis LD, Raines RT. Onconase cytotoxicity relies on the distribution of its positive charge. FEBS J. 2009; 276: 3846-57.
96. Stathopoulos GT, Moschos C, Loutrari H et al. Zoledronic acid is effective against experimental malignant pleural effusion. Am. J. Respir. Crit. Care Med. 2008; 178: 50-59.
97. Veltman JD, Lambers ME, van Nimwegen M et al. Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma. Br. J. Cancer 2010; 103: 629-41.
98. Jongsma J, van Montfort E, Vooijs M et al. A conditional mouse model for malignant mesothelioma. Cancer Cell 2008; 13: 261-71. (Pubitemid 351318370)
99. Krimpenfort P, Ijpenberg A, Song JY et al. p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a. Nature 2007; 448: 943-6. (Pubitemid 47312779)
100. López-Lago MA, Okada T, Murillo MM et al. Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependentmTORC1 signaling. Mol. Cell. Biol. 2009; 29: 4235-49.
101. Wilson SM, Barbone D, Yang TM et al. mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids. Am. J. Respir. Cell.Mol. Biol. 2008; 39: 576-83.
102. Velcheti V, Kasai Y, Viswanathan AK et al. Absence of mutations in the epidermal growth factor receptor (EGFR) kinase domain in patients with mesothelioma. J. Thorac. Oncol. 2009; 4: 559.
103. Wu SG, Gow CH, Yu CJ et al. Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma. Eur. Respir. J. 2008; 32: 924-30.
104. Garland LL, Rankin C, Gandara DR et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group study. J. Clin.Oncol. 2007; 25: 2406-13.
105. Menges CW, Chen Y, Mossman BT et al. A phosphotyrosine proteomic screen identifies multiple tyrosine kinase signaling pathways aberrantly activated in malignant mesothelioma. Genes Cancer 2010; 1: 493-505.
106. Shukla A, Bosenberg MW, MacPherson MB et al. Activated cAMP response element binding protein is overexpressed in human mesotheliomas and inhibits apoptosis. Am. J. Pathol. 2009; 175: 2197-206.
107. Graziani I, Eliasz S, De Marco MA et al. Opposite effects of Notch-1 and Notch-2 on mesothelioma cell survival under hypoxia are exerted through the Akt pathway. Cancer Res. 2008; 68: 9678-85.
108. Altomare DA, Menges CW, Pei J et al. Activated TNF-alpha/NFkappaB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas from Arf knockout mice. Proc. Natl. Acad. Sci. USA 2009; 106: 3420-25.
109. Stathopoulos GT, Sherrill TP, Cheng DS et al. Epithelial nuclear factor-kB activation promotes urethane-induced lung carcinogenesis. Proc. Natl. Acad. Sci. USA 2007; 104: 18514-19.
110. Sartore-Bianchi A, Gasparri F, Galvani A et al. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma. Clin. Cancer Res. 2007; 13: 5942-51.
111. Psallidas I, Karabela SP, Moschos C et al. Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study. Mol. Cancer 2010; 9: 56.
112. Yang H, Rivera Z, Jube S et al. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc. Natl. Acad. Sci. USA 2010; 107: 12611-6.
113. Stathopoulos GT, Kollintza A, Moschos C et al. Tumor necrosis factor-a promotes malignant pleural effusion. Cancer Res. 2007; 67: 9825-34. (Pubitemid 47621230)
114. Stathopoulos GT, Psallidas I, Moschos C et al. A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion. J. Natl. Cancer Inst. 2008; 100: 1464-76.
115. Cui R, Takahashi F, Ohashi R et al. Osteopontin is involved in the formation of malignant pleural effusion in lung cancer. Lung Cancer 2009; 63: 368-74.
116. Qin XJ, Shi HZ, Deng JM et al. CCL22 recruits CD4-positive CD25-positive regulatory T cells into malignant pleural effusion. Clin. Cancer Res. 2009; 15: 2231-7.
117. Moschos C, Psallidas I, Kollintza A et al. The angiopoietin/Tie2 axis mediates malignant pleural effusion formation. Neoplasia. 2009; 11: 298-304.
118. Fridlender ZG, Sun J, Kim S et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: 'N1' versus 'N2' TAN. Cancer Cell 2009; 16: 183-94.
119. Hegmans JP, Veltman JD, Lambers ME et al. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am. J. Respir. Crit. Care Med. 2010; 181: 1383-90.
120. Fridlender ZG, Buchlis G, Kapoor V et al. CCL2 blockade augments cancer immunotherapy. Cancer Res. 2010; 70: 109-18.
121. Stathopoulos GT, Sherrill TP, Karabela SP et al. Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion. Am. J. Respir. Crit. CareMed. 2010; 182: 1273-81.
122. Suzuki E, Kapoor V, Jassar AS et al. Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity. Clin. Cancer Res. 2005; 11: 6713-21.
123. Carroll RG, Carpenito C, Shan X et al. Distinct Effects of IL-18 on the Engraftment and Function of Human Effector CD8+ T Cells and Regulatory T Cells. PLoS ONE 2008; 3: e3289.
124. Carpenito C, Milone MC, Hassan R et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl. Acad. Sci. USA 2009; 106: 3360-65.
125. Bottomley A, Coens C, Efficace F et al. EORTC-NCIC. Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2007; 25: 5770-76.
126. Stone GW, Barzee S, Snarsky V et al. Regression of established AB1 murine mesothelioma induced by peritumoral injections of CpG oligodeoxynucleotide either alone or in combination with poly(I:C) and CD40 ligand plasmid DNA. J. Thorac. Oncol. 2009; 4: 802-8.
127. Yanagihara K, Tsumuraya M, Takigahira M et al. An orthotopic implantation mouse model of human malignant pleural mesothelioma for in vivo photon counting analysis and evaluation of the effect of S-1 therapy. Int. J. Cancer 2010; 126: 2835-46.
128. Hsia CCW, Hyde DM, Ochs M et al. on behalf of the ATS/ERS Joint Task Force on the Quantitative Assessment of Lung Structure. An official research policy statement of the American Thoracic Society/European Respiratory Society: standards for quantitative assessment of lung structure. Am. J. Respir. Crit. Care Med. 2010; 181: 394-418.
129. Amin W, Parwani AV, Schmandt L et al. National Mesothelioma Virtual Bank: a standard based biospecimen and clinical data resource to enhance translational research. BMC Cancer 2008; 8: 236.
130. Wakelee H, Loo BW Jr, Kernstine KH. Cooperative group research efforts in thoracic malignancies 2009: a review from the 10th Annual International Lung Cancer Congress. Clin. Lung Cancer 2009; 10: 395-404.